Findings of EMANATE, presented during ESC 2017 in Barcelona, trial support the use of apixaban in patient with atrial fibrillation undergoing cardioversion. The results discussed by Michael Ezekowitz (Sidney Kimmel Medical College).
ESC 2017: highlights from EMANATE trial
Dai congressiIntervisteCARDIOINFO@ESC2017
Scelti dall'editore
- ESC 2017: unmet needs in atrial fibrillation
We interviewed Robert P. Giugliano and Andreas Götte at Barcelona.
- Guida all’ESC 2017
Si svolgerà dal 26 al 30 agosto 2017 presso il centro congressi Fira Gran Via…